Novel Human Parechovirus 3 Diversity, Recombination, and Clinical Impact Across 7 Years: An Australian Story.
Australia
HPeV3
community
infants
parechovirus
pediatric
picornavirus
recombination
sepsis
viral evolution
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
11 01 2023
11 01 2023
Historique:
received:
23
12
2021
accepted:
21
07
2022
pubmed:
23
7
2022
medline:
14
1
2023
entrez:
22
7
2022
Statut:
ppublish
Résumé
A novel human parechovirus 3 Australian recombinant (HPeV3-AR) strain emerged in 2013 and coincided with biennial outbreaks of sepsis-like illnesses in infants. We evaluated the molecular evolution of the HPeV3-AR strain and its association with severe HPeV infections. HPeV3-positive samples collected from hospitalized infants aged 5-252 days in 2 Australian states (2013-2020) and from a community-based birth cohort (2010-2014) were sequenced. Coding regions were used to conduct phylogenetic and evolutionary analyses. A recombinant-specific polymerase chain reaction was designed and utilized to screen all clinical and community HPeV3-positive samples. Complete coding regions of 54 cases were obtained, which showed the HPeV3-AR strain progressively evolving, particularly in the 3' end of the nonstructural genes. The HPeV3-AR strain was not detected in the community birth cohort until the initial outbreak in late 2013. High-throughput screening showed that most (>75%) hospitalized HPeV3 cases involved the AR strain in the first 3 clinical outbreaks, with declining prevalence in the 2019-2020 season. The AR strain was not statistically associated with increased clinical severity among hospitalized infants. HPeV3-AR was the dominant strain during the study period. Increased hospital admissions may have been from a temporary fitness advantage and/or increased virulence.
Sections du résumé
BACKGROUND
A novel human parechovirus 3 Australian recombinant (HPeV3-AR) strain emerged in 2013 and coincided with biennial outbreaks of sepsis-like illnesses in infants. We evaluated the molecular evolution of the HPeV3-AR strain and its association with severe HPeV infections.
METHODS
HPeV3-positive samples collected from hospitalized infants aged 5-252 days in 2 Australian states (2013-2020) and from a community-based birth cohort (2010-2014) were sequenced. Coding regions were used to conduct phylogenetic and evolutionary analyses. A recombinant-specific polymerase chain reaction was designed and utilized to screen all clinical and community HPeV3-positive samples.
RESULTS
Complete coding regions of 54 cases were obtained, which showed the HPeV3-AR strain progressively evolving, particularly in the 3' end of the nonstructural genes. The HPeV3-AR strain was not detected in the community birth cohort until the initial outbreak in late 2013. High-throughput screening showed that most (>75%) hospitalized HPeV3 cases involved the AR strain in the first 3 clinical outbreaks, with declining prevalence in the 2019-2020 season. The AR strain was not statistically associated with increased clinical severity among hospitalized infants.
CONCLUSIONS
HPeV3-AR was the dominant strain during the study period. Increased hospital admissions may have been from a temporary fitness advantage and/or increased virulence.
Identifiants
pubmed: 35867852
pii: 6648722
doi: 10.1093/infdis/jiac311
pmc: PMC9833435
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
278-287Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Eur J Radiol. 2016 Feb;85(2):428-34
pubmed: 26781149
J Med Microbiol. 2015 Nov;64(11):1415-1424
pubmed: 26358716
J Med Virol. 2012 Apr;84(4):686-90
pubmed: 22337310
Thorax. 2018 Oct;73(10):969-979
pubmed: 29247051
J Gen Virol. 2010 Jan;91(Pt 1):145-54
pubmed: 19759239
Sci Rep. 2017 Mar 14;7:44423
pubmed: 28290509
J Med Virol. 2010 Oct;82(10):1790-6
pubmed: 20827778
Pediatr Infect Dis J. 2019 Jan;38(1):1-5
pubmed: 30204658
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
J Clin Virol. 2017 Jan;86:39-45
pubmed: 27914285
J Pediatr. 2021 Feb;229:216-222.e2
pubmed: 33045237
Emerg Infect Dis. 2016 Sep;22(9):1631-4
pubmed: 27532333
Arch Dis Child. 2018 Nov;103(11):1061-1066
pubmed: 29871901
Mediators Inflamm. 2020 Jan 31;2020:9273241
pubmed: 32089650
Sci Rep. 2017 Jun 20;7(1):3861
pubmed: 28634337
Clin Infect Dis. 2006 Jan 15;42(2):204-10
pubmed: 16355330
J Gen Virol. 2008 Apr;89(Pt 4):1030-1035
pubmed: 18343846
Pediatr Infect Dis J. 2011 Mar;30(3):238-42
pubmed: 20948454
Arch Dis Child. 2019 Jun;104(6):552-557
pubmed: 30530486
J Gen Virol. 2010 May;91(Pt 5):1229-38
pubmed: 20089803
J Gen Virol. 2004 Feb;85(Pt 2):391-398
pubmed: 14769896
Clin Infect Dis. 2020 Jun 24;71(1):116-127
pubmed: 31406985
Emerg Infect Dis. 2015 Nov;21(11):1966-72
pubmed: 26485714
Adv Pediatr. 2011;58(1):65-85
pubmed: 21736976
Euro Surveill. 2014 Apr 17;19(15):
pubmed: 24762664
Sci Rep. 2019 Jun 20;9(1):8906
pubmed: 31222066
Infect Dis Clin North Am. 2015 Sep;29(3):415-28
pubmed: 26188604
Genetics. 1989 Nov;123(3):585-95
pubmed: 2513255
BMJ Open. 2012 Oct 31;2(6):
pubmed: 23117571
J Paediatr Child Health. 2022 May;58(5):856-862
pubmed: 34967960
Emerg Infect Dis. 2019 Jan;25(1):148-152
pubmed: 30561318